The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance
Open accessAbstract
Overexpression of drug efflux transporters such as P-glycoprotein (P-gp) enables cancer cells to develop resistance to multiple anticancer drugs. Functional inhibitors of P-gp have shown promising efficacy in early clinical trials, but their long-term safety is yet to be established. A novel approach to overcome drug resistance is to use siRNA-mediated RNA interference to silence the expression of the efflux transporter. Because P-gp plays an important role in the physiological regulation of endogenous and xenobiotic compounds in the body, it is important to deliver P-gp targeted siRNA and anticancer drug specifically to tumor cells. Further, for optimal synergy, both the drug and siRNA may need to be temporally colocalized in the tumor cells. In the current study, we investigated the effectiveness of simultaneous and targeted delivery of anticancer drug, paclitaxel, along with P-gp targeted siRNA, using poly(D,L-lactide-co-glycolide) nanoparticles to overcome tumor drug resistance. Nanoparticles were surface functionalized with biotin for active tumor targeting. Dual agent nanoparticles encapsulating the combination of paclitaxel and P-gp targeted siRNA showed significantly higher cytotoxicity in vitro than nanoparticles loaded with paclitaxel alone. Enhanced therapeutic efficacy of dual agent nanoparticles could be correlated with effective silencing of the MDR1 gene that encodes for P-gp and with increased accumulation of paclitaxel in drug-resistant tumor cells. In vivo studies in a mouse model of drug-resistant tumor demonstrated significantly greater inhibition of tumor growth following treatment with biotin-functionalized nanoparticles encapsulating both paclitaxel and P-gp targeted siRNA at a paclitaxel dose that was ineffective in the absence of gene silencing. These results suggest that that the combination of P-gp gene silencing and cytotoxic drug delivery using targeted nanoparticles can overcome tumor drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
Self-citationMultidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,026
Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles
Wischke, C., & Schwendeman, S. P. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.042 · Cited by 790
Super pH-Sensitive Multifunctional Polymeric Micelle
Lee, E. S., Na, K., & Bae, Y. H. (2005) · Nano Letters · doi:10.1021/nl0479987 · Cited by 611
ABC Transporters, Drug Resistance, and Cancer Stem Cells
Dean, M. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9109-9 · Cited by 425
Cationic lipids and polymers mediated vectors for delivery of siRNA
Zhang, S., Zhao, B., Jiang, H., Wang, B., & Ma, B. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.07.016 · Cited by 421
Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours
Russell-Jones, G., McTavish, K., McEwan, J., Rice, J., & Nowotnik, D. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.07.009 · Cited by 392
Patil, Y., Sadhukha, T., Ma, L., & Panyam, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.021 · Cited by 317
Self-citationDong, X., Mattingly, C. A., Tseng, M. T., Cho, M. J., Liu, Y., Adams, V. R., & Mumper, R. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2747 · Cited by 290
Emilienne Soma, C., Dubernet, C., Bentolila, D., Benita, S., & Couvreur, P. (2000) · Biomaterials · doi:10.1016/s0142-9612(99)00125-8 · Cited by 281
Sun, B., Ranganathan, B., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.09.038 · Cited by 274
MacDiarmid, J. A., Amaro-Mugridge, N. B., Madrid-Weiss, J., Sedliarou, I., Wetzel, S., Kochar, K., Brahmbhatt, V. N., Phillips, L., Pattison, S. T., Petti, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1547 · Cited by 272
Polymeric nanoparticles for siRNA delivery and gene silencing
Patil, Y., & Panyam, J. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.09.039 · Cited by 270
Self-citationPLGA-based drug delivery systems: Importance of the type of drug and device geometry
Klose, D., Siepmann, F., Elkharraz, K., & Siepmann, J. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.10.030 · Cited by 267
Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery
Patil, Y. B., Toti, U. S., Khdair, A., Ma, L., & Panyam, J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.09.056 · Cited by 242
Self-citationClinical trials of p-glycoprotein reversal in solid tumours
Ferry, D. R., Traunecker, H., & Kerr, D. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00091-3 · Cited by 214
Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA–PEG–folate conjugate
Esmaeili, F., Ghahremani, M. H., Ostad, S. N., Atyabi, F., Seyedabadi, M., Malekshahi, M. R., Amini, M., & Dinarvand, R. (2008) · Journal of Drug Targeting · doi:10.1080/10611860802088630 · Cited by 203
Choi, S.-W., & Kim, J.-H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.06.003 · Cited by 196
Panyam, J., & Labhasetwar, V. (2004) · Molecular Pharmaceutics · doi:10.1021/mp034002c · Cited by 195
Self-citationde Verdière, A., Dubernet, C., Némati, F., Soma, E., Appel, M., Ferté, J., Bernard, S., Puisieux, F., & Couvreur, P. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.362 · Cited by 168
Linnet, K., & Ejsing, T. B. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.06.003 · Cited by 163
Multidrug Resistance/P-Glycoprotein and Breast Cancer: Review and Meta-Analysis
Clarke, R., Leonessa, F., & Trock, B. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.009 · Cited by 159
Yadav, S. K., van Vlerken, L. E., Little, S. R., & Amiji, M. M. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0790-y · Cited by 152
Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P. R., Villalona, M. A., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L. A., Kraynak, M. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2964 · Cited by 146
Kano, M. R., Komuta, Y., Iwata, C., Oka, M., Shirai, Y.-T., Morishita, Y., Ouchi, Y., Kataoka, K., & Miyazono, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.01003.x · Cited by 125
Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux
Chavanpatil, M. D., Patil, Y. B., & Panyam, J. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.03.045 · Cited by 124
Self-citationSurfactant–Polymer Nanoparticles Overcome P-Glycoprotein-Mediated Drug Efflux
Chavanpatil, M. D., Khdair, A., Gérard, B., Bachmeier, C. J., Miller, D. W., Shekhar, M. P. V., & Panyam, J. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070024d · Cited by 117
Self-citationTakahashi, Y., Nishikawa, M., & Takakura, Y. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.006 · Cited by 110
Hubensack, M., Müller, C., Höcherl, P., Fellner, S., Spruß, T., Bernhardt, G., & Buschauer, A. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0323-9 · Cited by 97
In vivo RNA Interference–Mediated Ablation of MDR1 P-Glycoprotein
Pichler, A., Zelcer, N., Prior, J. L., Kuil, A., & Piwnica-Worms, D. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0038 · Cited by 97
Yagüe, E., Higgins, C. F., & Raguz, S. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302269 · Cited by 94
Xu, D., McCarty, D. M., Fernandes, A., Fisher, M. H., Samulski, R. J., & Juliano, R. L. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.019 · Cited by 88
Salem, A. K., Cannizzaro, S. M., Davies, M. C., Tendler, S. J. B., Roberts, C. J., Williams, P. M., & Shakesheff, K. M. (2001) · Biomacromolecules · doi:10.1021/bm010030+ · Cited by 84
Berkland, C. J., Pollauf, E. J., Raman, C., Silverman, R., Kim, K., & Pack, D. W. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20948 · Cited by 78
Relevance of multidrug resistance in the age of targeted therapy.
Türk, D., & Szakács, G. (2009) · PubMed · Cited by 52
Juan, B. S. D., von Briesen, H., Gelperina, S. E., & Kreuter, J. (2006) · Journal of drug targeting · doi:10.1080/10611860600866872 · Cited by 51
Xu, D., Ye, D., Fisher, M., & Juliano, R. L. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033639 · Cited by 47
What does Multidrug Resistance (MDR) Expression Mean in the Clinic?
Duhem, C., Ries, F., & Dicato, M. A. (1996) · The Oncologist · doi:10.1634/theoncologist.1-3-151 · Cited by 46
Surface‐functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium
Sundaram, S., Roy, S. K., Ambati, B. K., & Kompella, U. B. (2009) · The FASEB Journal · doi:10.1096/fj.09-129825 · Cited by 43
Acute and chronic in vivo therapeutic resistance
Teicher, B. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.01.006 · Cited by 42
Targeting P-glycoprotein for Effective Oral Anti-Cancer Chemotherapeutics
Bebawy, M., & Sze, D. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783497168 · Cited by 20
Cited by
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Lu, J., Liong, M., Li, Z., Zink, J. I., & Tamanoi, F. (2010) · Small · doi:10.1002/smll.201000538 · Cited by 1,074
Metadata
- Authors
- Patil, Y. B., Swaminathan, S. K., Sadhukha, T., Ma, L., & Panyam, J.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 31
- Issue
- 2
- Pages
- 358-365
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2013270956
- Cited by
- 304
- References
- 46
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.